RT Journal Article
SR Electronic
T1 Assessing the Performance of the Birmingham Vasculitis Activity Score at Diagnosis for Children with Antineutrophil Cytoplasmic Antibody-associated Vasculitis in A Registry for Childhood Vasculitis (ARChiVe)
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 1088
OP 1094
DO 10.3899/jrheum.111030
VO 39
IS 5
A1 KIMBERLY MORISHITA
A1 SUZANNE C. LI
A1 EYAL MUSCAL
A1 STEVEN SPALDING
A1 JAIME GUZMAN
A1 AMERICA URIBE
A1 LESLIE ABRAMSON
A1 KEVIN BASZIS
A1 SUSANNE BENSELER
A1 SUZANNE BOWYER
A1 SARAH CAMPILLO
A1 PETER CHIRA
A1 AIMEE O. HERSH
A1 GLORIA HIGGINS
A1 ANNE EBERHARD
A1 KALEO EDE
A1 LISA IMUNDO
A1 LAWRENCE JUNG
A1 SUSAN KIM
A1 DANIEL J. KINGSBURY
A1 MARISA KLEIN-GITELMAN
A1 ERICA F. LAWSON
A1 DANIEL J. LOVELL
A1 THOMAS MASON
A1 DEBORAH McCURDY
A1 KABITA NANDA
A1 LORIEN NASSI
A1 KATHLEEN M. O’NEIL
A1 EGLA RABINOVICH
A1 SUZANNE E. RAMSEY
A1 ANDREAS REIFF
A1 MARGALIT ROSENKRANZ
A1 KENNETH SCHIKLER
A1 ANNE STEVENS
A1 DAWN WAHEZI
A1 DAVID A. CABRAL
YR 2012
UL http://www.jrheum.org/content/39/5/1088.abstract
AB Objective. There are no validated tools for measuring disease activity in pediatric vasculitis. The Birmingham Vasculitis Activity Score (BVAS) is a valid disease activity tool in adult vasculitis. Version 3 (BVAS v.3) correlates well with physician’s global assessment (PGA), treatment decision, and C-reactive protein in adults. The utility of BVAS v.3 in pediatric vasculitis is not known. We assessed the association of BVAS v.3 scores with PGA, treatment decision, and erythrocyte sedimentation rate (ESR) at diagnosis in pediatric antineutrophil cytoplasmic antibody-associated vasculitis (AAV). Methods. Children with AAV diagnosed between 2004 and 2010 at all ARChiVe centers were eligible. BVAS v.3 scores were calculated with a standardized online tool (www.vasculitis.org). Spearman’s rank correlation coefficient (rs) was used to test the strength of association between BVAS v.3 and PGA, treatment decision, and ESR. Results. A total of 152 patients were included. The physician diagnosis of these patients was predominantly granulomatosis with polyangiitis (n = 99). The median BVAS v.3 score was 18.0 (range 0–40). The BVAS v.3 correlations were rs = 0.379 (95% CI 0.233 to 0.509) with PGA, rs = 0.521 (95% CI 0.393 to 0.629) with treatment decision, and rs = 0.403 (95% CI 0.253 to 0.533) with ESR. Conclusion. Applied to children with AAV, BVAS v.3 had a weak correlation with PGA and moderate correlation with both ESR and treatment decision. Prospective evaluation of BVAS v.3 and/or pediatric-specific modifications to BVAS v.3 may be required before it can be formalized as a disease activity assessment tool in pediatric AAV.